English

Beta Bionics, Inc.

EDGAR

BBNX Current report (8-K) · filed 2026-10-27

Annual consolidated revenue for 2025: about USD 100.3M, using the latest reported figures. The previous period, 2024, was about USD 65.12M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

35.5 million USD

2026 Q3 · USD

Exact inputs and evidence

Revenue: 35505000 USD Source

Operating margin

-74.94%

2026 Q3 · %

Exact inputs and evidence

Operating Income: -26609000 USD Source
Revenue: 35505000 USD Source

Operating cash flow

-12.3 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -50741000 USD Source
Operating Cash Flow: -38454000 USD Source

Free cash flow

-14.6 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -50741000 USD Source
Operating Cash Flow: -38454000 USD Source
Capital Expenditure: 4691000 USD Source
Capital Expenditure: 2416000 USD Source

Cash and cash equivalents: 81.6 million USD 2026-09-30 Source
Exact value

81551000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 54.4 million shares 2026-09-30 Source
Exact value

54362972 shares

Reported share-count change

23.58% · 10.4 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

43991598 shares · 2025-09-30· Source
54362972 shares · 2026-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

127 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Revenue: 100251000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 68130000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 27626000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 32013000 USD · 2026-04-01 – 2026-06-30 Source
Revenue: 35505000 USD · 2026-07-01 – 2026-09-30 Source

Net income

-83.1 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Net income: -73200000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -59734000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -21895000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -23403000 USD · 2026-04-01 – 2026-06-30 Source
Net income: -24353000 USD · 2026-07-01 – 2026-09-30 Source

Operating cash flow

-59.4 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Operating cash flow: -50925000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -42298000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -23832000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -38454000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -23832000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -50741000 USD · 2026-01-01 – 2026-09-30 Source
Operating cash flow: -38454000 USD · 2026-01-01 – 2026-06-30 Source

Capital expenditure

6.59 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Capital expenditure: 5297000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 3394000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1377000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 2416000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1377000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 4691000 USD · 2026-01-01 – 2026-09-30 Source
Capital expenditure: 2416000 USD · 2026-01-01 – 2026-06-30 Source

Free cash flow

-66 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence

Operating cash flow: -50925000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -42298000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -23832000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -38454000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -23832000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -50741000 USD · 2026-01-01 – 2026-09-30 Source
Operating cash flow: -38454000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 5297000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 3394000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1377000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 2416000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 1377000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 4691000 USD · 2026-01-01 – 2026-09-30 Source
Capital expenditure: 2416000 USD · 2026-01-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-27.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: 3 of 11 periods available· newest 2025-12-31
Total liabilities: 3 of 11 periods available· newest 2025-12-31
Current assets: 3 of 11 periods available· newest 2025-12-31
Current liabilities: 3 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+53.9%

Prior period

USD 65.12 million

2024-01-01 – 2024-12-31
Current period

USD 100.25 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

100251000 − 65124000 = 35127000 USD

65124000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
100251000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Beta Bionics, Inc. · 2025-12-31 Beta Bionics, Inc. (edgar:1674632) Year-over-year change in Revenue: 35127000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 100251000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3382927 Filing: 000119312526067065 Input fundies:Revenue: 65124000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3384811 Filing: 000119312526067065
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 18.44 million

Prior period

−USD 54.76 million

2024-01-01 – 2024-12-31
Current period

−USD 73.2 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-73200000 − -54756000 = -18444000 USD

-54756000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-73200000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Beta Bionics, Inc. · 2025-12-31 Beta Bionics, Inc. (edgar:1674632) Year-over-year change in Net income: -18444000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -73200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#4592784 Filing: 000119312526067065 Input fundies:NetIncome: -54756000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#4594599 Filing: 000119312526067065
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 2.65 million

Prior period

−USD 48.27 million

2024-01-01 – 2024-12-31
Current period

−USD 50.93 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-50925000 − -48273000 = -2652000 USD

-48273000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-50925000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Beta Bionics, Inc. · 2025-12-31 Beta Bionics, Inc. (edgar:1674632) Year-over-year change in Operating cash flow: -2652000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -50925000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3014024 Filing: 000119312526067065 Input fundies:OperatingCashFlow: -48273000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3016006 Filing: 000119312526067065
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+56%

Prior period

USD 3.4 million

2024-01-01 – 2024-12-31
Current period

USD 5.3 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

5297000 − 3395000 = 1902000 USD

3395000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
5297000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Beta Bionics, Inc. · 2025-12-31 Beta Bionics, Inc. (edgar:1674632) Year-over-year change in Capital expenditure: 1902000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 5297000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3036654 Filing: 000119312526067065 Input fundies:CapitalExpenditure: 3395000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3038626 Filing: 000119312526067065
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 100.25 million 100% of revenue
Cost of revenue USD 44.71 million 45% of revenue
Operating expenses USD 127.22 million 127% of revenue
Operating income −USD 71.68 million −72% of revenue
Tax, interest and other Derived USD 1.52 million 1.5% of revenue
Net income −USD 73.2 million −73% of revenue

Cash

Operating cash flow −USD 50.93 million −51% of revenue
Capital expenditure USD 5.3 million 5.3% of revenue
Free cash flow Derived −USD 56.22 million −56% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Operating loss: operating costs were 399% of revenue.
2024 Operating loss: operating costs were 169% of revenue.
2025 Operating loss: operating costs were 172% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	11995000	47845000 Derived	-35850000	8249000 Derived	-44099000	-32847000 Derived	Source 2023-01-01 – 2023-12-31: 11995000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -35850000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -44099000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -32445000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 402000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	65124000	110375000 Derived	-45251000	9505000 Derived	-54756000	-51668000 Derived	Source 2024-01-01 – 2024-12-31: 65124000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -45251000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -54756000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -48273000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 3395000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	100251000	171932000 Derived	-71681000	1519000 Derived	-73200000	-56222000 Derived	Source 2025-01-01 – 2025-12-31: 100251000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -71681000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -73200000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -50925000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 5297000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 100.3M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Revenue	11995000	Revenue: 11995000 Open source
20242024-12-31	Revenue	65124000	Revenue: 65124000 Open source
20252025-12-31	Revenue	100251000	Revenue: 100251000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

53.9% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 11995000 Open source
20242024-12-31	Year over year	442.9%	Revenue: 65124000 Open source Revenue: 11995000 Open source
20252025-12-31	Year over year	53.9%	Revenue: 100251000 Open source Revenue: 65124000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -71.5% 2025

Net margin -73% 2025

Free cash flow margin -56.1% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	-298.9%	Operating Income: -35850000 Open source Revenue: 11995000 Open source
20242024-12-31	Operating margin	-69.5%	Operating Income: -45251000 Open source Revenue: 65124000 Open source
20252025-12-31	Operating margin	-71.5%	Operating Income: -71681000 Open source Revenue: 100251000 Open source
20232023-12-31	Net margin	-367.6%	Net Income: -44099000 Open source Revenue: 11995000 Open source
20242024-12-31	Net margin	-84.1%	Net Income: -54756000 Open source Revenue: 65124000 Open source
20252025-12-31	Net margin	-73%	Net Income: -73200000 Open source Revenue: 100251000 Open source
20232023-12-31	Free cash flow margin	-273.8%	Revenue: 11995000 Open source Operating Cash Flow: -32445000 Open source Capital Expenditure: 402000 Open source
20242024-12-31	Free cash flow margin	-79.3%	Revenue: 65124000 Open source Operating Cash Flow: -48273000 Open source Capital Expenditure: 3395000 Open source
20252025-12-31	Free cash flow margin	-56.1%	Revenue: 100251000 Open source Operating Cash Flow: -50925000 Open source Capital Expenditure: 5297000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -50.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Operating cash flow	-32445000	Operating Cash Flow: -32445000 Open source
20242024-12-31	Operating cash flow	-48273000	Operating Cash Flow: -48273000 Open source
20252025-12-31	Operating cash flow	-50925000	Operating Cash Flow: -50925000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -56.2M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Free cash flow	-32847000	Operating Cash Flow: -32445000 Open source Capital Expenditure: 402000 Open source
20242024-12-31	Free cash flow	-51668000	Operating Cash Flow: -48273000 Open source Capital Expenditure: 3395000 Open source
20252025-12-31	Free cash flow	-56222000	Operating Cash Flow: -50925000 Open source Capital Expenditure: 5297000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

12.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Liabilities / assets	46.7%	Total Liabilities: 51432000 Open source Total Assets: 110040000 Open source
20242024-12-31	Liabilities / assets	49.2%	Total Liabilities: 73632000 Open source Total Assets: 149645000 Open source
20252025-12-31	Liabilities / assets	12.5%	Total Liabilities: 41133000 Open source Total Assets: 328743000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

8.66× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Current assets / current liabilities	9.77×	Current Assets: 103621000 Open source Current Liabilities: 10605000 Open source
20242024-12-31	Current assets / current liabilities	6.29×	Current Assets: 132923000 Open source Current Liabilities: 21148000 Open source
20252025-12-31	Current assets / current liabilities	8.66×	Current Assets: 267905000 Open source Current Liabilities: 30924000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−USD 44.1 million Exact value Exact value: -44099000 USD 2023-01-01 – 2023-12-31: -44099000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Beta Bionics, Inc. · 2023-12-31 Beta Bionics, Inc. (edgar:1674632) Net Income: -44099000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -44099000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000095017025046762/bbnx-20241231.htm#5580882 Filing: 000095017025046762 The citation records this snapshot. The page link may show a newer release later.	−USD 32.45 million Exact value Exact value: -32445000 USD 2023-01-01 – 2023-12-31: -32445000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Beta Bionics, Inc. · 2023-12-31 Beta Bionics, Inc. (edgar:1674632) Operating Cash Flow: -32445000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32445000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000095017025046762/bbnx-20241231.htm#4107438 Filing: 000095017025046762 The citation records this snapshot. The page link may show a newer release later.	USD 402,000 Exact value Exact value: 402000 USD 2023-01-01 – 2023-12-31: 402000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Beta Bionics, Inc. · 2023-12-31 Beta Bionics, Inc. (edgar:1674632) Capital Expenditure: 402000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 402000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000095017025046762/bbnx-20241231.htm#4124985 Filing: 000095017025046762 The citation records this snapshot. The page link may show a newer release later.	−USD 32.85 million Calculation and evidence -32445000 − 402000 USD Exact free cash flow: -32847000 USD 2023-01-01 – 2023-12-31: -32445000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 402000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Beta Bionics, Inc. · 2023-12-31 Beta Bionics, Inc. (edgar:1674632) Free cash flow: -32847000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32445000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000095017025046762/bbnx-20241231.htm#4107438 Filing: 000095017025046762 Input fundies:CapitalExpenditure: 402000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000095017025046762/bbnx-20241231.htm#4124985 Filing: 000095017025046762 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 54.76 million Exact value Exact value: -54756000 USD 2024-01-01 – 2024-12-31: -54756000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Beta Bionics, Inc. · 2024-12-31 Beta Bionics, Inc. (edgar:1674632) Net Income: -54756000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -54756000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#4594599 Filing: 000119312526067065 The citation records this snapshot. The page link may show a newer release later.	−USD 48.27 million Exact value Exact value: -48273000 USD 2024-01-01 – 2024-12-31: -48273000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Beta Bionics, Inc. · 2024-12-31 Beta Bionics, Inc. (edgar:1674632) Operating Cash Flow: -48273000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48273000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3016006 Filing: 000119312526067065 The citation records this snapshot. The page link may show a newer release later.	USD 3.4 million Exact value Exact value: 3395000 USD 2024-01-01 – 2024-12-31: 3395000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Beta Bionics, Inc. · 2024-12-31 Beta Bionics, Inc. (edgar:1674632) Capital Expenditure: 3395000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3395000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3038626 Filing: 000119312526067065 The citation records this snapshot. The page link may show a newer release later.	−USD 51.67 million Calculation and evidence -48273000 − 3395000 USD Exact free cash flow: -51668000 USD 2024-01-01 – 2024-12-31: -48273000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3395000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Beta Bionics, Inc. · 2024-12-31 Beta Bionics, Inc. (edgar:1674632) Free cash flow: -51668000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48273000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3016006 Filing: 000119312526067065 Input fundies:CapitalExpenditure: 3395000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3038626 Filing: 000119312526067065 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 73.2 million Exact value Exact value: -73200000 USD 2025-01-01 – 2025-12-31: -73200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Beta Bionics, Inc. · 2025-12-31 Beta Bionics, Inc. (edgar:1674632) Net Income: -73200000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#4592784 Filing: 000119312526067065 The citation records this snapshot. The page link may show a newer release later.	−USD 50.93 million Exact value Exact value: -50925000 USD 2025-01-01 – 2025-12-31: -50925000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Beta Bionics, Inc. · 2025-12-31 Beta Bionics, Inc. (edgar:1674632) Operating Cash Flow: -50925000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -50925000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3014024 Filing: 000119312526067065 The citation records this snapshot. The page link may show a newer release later.	USD 5.3 million Exact value Exact value: 5297000 USD 2025-01-01 – 2025-12-31: 5297000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Beta Bionics, Inc. · 2025-12-31 Beta Bionics, Inc. (edgar:1674632) Capital Expenditure: 5297000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5297000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3036654 Filing: 000119312526067065 The citation records this snapshot. The page link may show a newer release later.	−USD 56.22 million Calculation and evidence -50925000 − 5297000 USD Exact free cash flow: -56222000 USD 2025-01-01 – 2025-12-31: -50925000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 5297000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Beta Bionics, Inc. · 2025-12-31 Beta Bionics, Inc. (edgar:1674632) Free cash flow: -56222000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T20:04:25Z Snapshot: 2ec2bf2d6b5bed76f7329df046ec6a860b91545542e24469273a43843058990d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674632?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -50925000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3014024 Filing: 000119312526067065 Input fundies:CapitalExpenditure: 5297000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674632/000119312526067065/bbnx-20251231.htm#3036654 Filing: 000119312526067065 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

14 filings · 824 latest values · 824 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001674632, 1674632, BBNX, edgar:1674632

Also known as BETA BIONICS, INC., Beta Bionics, Inc, Beta Bionics, Inc.

Beta Bionics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation